This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Will Positive Camzyos Data Strengthen BMY's Cardiovascular Portfolio?
by Ekta Bagri
BMY's Camzyos shows strong late-stage results in adolescent heart disease, boosting hopes for expanded use as cardiovascular portfolio faces mixed developments.
BMYPositive Net Change JNJNo Net Change PFENegative Net Change CYTKNegative Net Change
biotechnology biotechs medical pharmaceuticals
RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease
by Zacks Equity Research
Rocket Pharmaceuticals drops despite the FDA's accelerated approval of gene therapy Kresladi in severe leukocyte adhesion deficiency-I, an ultra-rare disease.
PRTANegative Net Change ANIPPositive Net Change RCKTNo Net Change REPLPositive Net Change
biotechs
AZN Stock Gains as COPD Drug Clears Two Late-Stage Studies
by Zacks Equity Research
AstraZeneca jumps as tozorakimab hits primary goals in two phase III COPD trials, cuts exacerbations and shows promise in a disease with limited options.
REGNNegative Net Change SNYNegative Net Change AZNPositive Net Change RHHBYPositive Net Change
biotechs medical pharmaceuticals
Novartis Bolsters Immunology Pipeline With Excellergy Deal
by Zacks Equity Research
Novartis targets IgE-driven diseases with Excellergy buy, adding a phase I anti-IgE asset to boost its immunology pipeline and allergy franchise.
NVSPositive Net Change ANIPPositive Net Change ADMAPositive Net Change LQDAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk's Awiqli Gets FDA Approval for Type II Diabetes
by Zacks Equity Research
NVO secures FDA nod for Awiqli, a once-weekly basal insulin for type II diabetes, strengthening its portfolio and showing strong efficacy in studies.
NVONegative Net Change CPRXPositive Net Change INONegative Net Change ADMAPositive Net Change
biotechs
KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate
by Zacks Equity Research
Kodiak Sciences rallies 75% as phase III GLOW2 data show Zenkuda's strong efficacy, safety and risk reduction in diabetic retinopathy patients.
CPRXPositive Net Change INONegative Net Change ADMAPositive Net Change KODPositive Net Change
biotechs
WVE Posts Interim Data From Phase I Study on WVE-007, Stock Tanks
by Zacks Equity Research
Wave Life Sciences stock plunges after interim phase I data for WVE-007 showed modest fat reduction at higher dose, despite some sustained benefits.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change WVEPositive Net Change
biotechs
VKTX Finishes Enrollment in Second Late-Stage Study on Obesity Drug
by Zacks Equity Research
Viking Therapeutics climbs after it completes enrollment in the second phase III obesity study for VK2735 and advances its bid in a fast-growing, competitive weight-loss market.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential?
by Sundeep Ganoria
IBRX and MRNA hinge on single-drug success, but pipeline depth, growth plans and risks set them apart in the race for biotech upside.
MRKNegative Net Change MRNANegative Net Change IBRXPositive Net Change
biotechs medical medical-devices messenger-rna pharmaceuticals vaccines
Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?
by Zacks Equity Research
Gilead doubles down on acquisitions, adding immunology and CAR-T assets to diversify beyond HIV and strengthen its oncology pipeline.
NVSPositive Net Change BMYPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals